Micro-Fragmented Fat Composition for Acute and Late Sepsis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for sepsis are not very effective, leading to high mortality rates and long-term complications such as neuromyopathy, muscle weakness, and organ dysfunction, with existing therapies failing to address the systemic inflammatory response and cytokine storm effectively.

Innovation Solution

Administration of micro-fragmented fat tissue, preferably obtained using the Lipogems® device, which maintains the stromal vascular niche and contains Mesenchymal Stem Cells (MSCs) and pericytes, administered intraperitoneally to treat sepsis, reducing pro-inflammatory cytokines and increasing anti-inflammatory cytokines.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for sepsis, then standard medical care is provided, but mortality rates remain high and long-term complications occur

Engineering Contradiction:

Improveeffectiveness of sepsis treatmentVSAvoidmortality rate and long-term complications

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses micro-fragmented fat tissue as an intermediary substance to mediate the treatment of sepsis. The adipose-derived stem cells and extracellular matrix in the micro-fragmented fat tissue act as biological mediators that modulate the immune response, reduce inflammation, and promote tissue repair, thereby improving treatment effectiveness and reducing harmful outcomes

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the physical and biological parameters of the treatment by using micro-fragmented fat tissue with specific characteristics (cell composition, matrix structure, growth factors) instead of conventional medications. This parameter change enables the treatment to address multiple aspects of sepsis simultaneously, improving reliability while reducing complications

Inventive Principle:

Principle #35Parameter changes

2Reliability

If sepsis treatment is delayed or ineffective, then acute phase survival may be achieved, but late phase complications such as neuromyopathy and muscle weakness develop

Engineering Contradiction:

Improvesurvival rateVSAvoidneuromyopathy and muscle weakness

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The micro-fragmented fat tissue is administered during the acute phase of sepsis as a preliminary action to prevent the development of late-phase complications. The stem cells and bioactive factors in the treatment prepare the body's regenerative systems in advance, preventing neuromyopathy and muscle weakness before they can develop

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The treatment converts the harmful inflammatory response and tissue damage caused by sepsis into beneficial regenerative processes. The micro-fragmented fat tissue stimulates the body's natural repair mechanisms, transforming the pathological state into a healing state that prevents long-term complications

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS12551507B2Fat and medical uses thereof

Publication Date: 2026.02.17 LIPOGEMS INT SRL

AI summary

The present invention refers to micro-fragmented fat or a composition comprising micro-fragmented fat for use in the treatment of a systemic disease, preferably associated to or caused by sepsis. Moreover, the micro-fragmented fat or the composition comprising micro-fragmented fat is used for treating a systemic, inflammatory, immune, or chronic disease, said disease being intended as a consequence of septic disease. Preferably, the micro-fragmented fat is useful for treating both the acute (early) and late stages of sepsis.